ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

IMCR vs TSHA // REVENUE GROWTH (YOY)

Immunocore Holdings plc (NASDAQ) VS. Taysha Gene Therapies Inc. (NASDAQ) • 15-METRIC TALLY: IMCR 7 — TSHA 1
▲ REVENUE GROWTH (YOY) LEADER: IMCR
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IMCR VS. TSHA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC IMCR TSHA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 96.00% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -0.93% -6.82% +5.89 IMCR /fcf-yield <GO>
Operating Margin -11.30% -60.00% +48.70 IMCR /operating-margins <GO>
Net Profit Margin -8.90% -60.00% +51.10 IMCR /net-margins <GO>
Revenue Growth (YoY) ACTIVE 29.00% 17.30% +11.70 IMCR /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 1.40 5.67 -4.27 TSHA /balance-sheet <GO>
Piotroski F-Score Quality 5/9 4/9 +1.00 IMCR /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.4 43.8 +2.62 IMCR /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.61B $1.38B $235.3M IMCR /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR IMCR REV TSHA REV IMCR GROSS % TSHA GROSS % IMCR FCF TSHA FCF
FY 2025 $400.0M $9.8M 98.0% — -$15.1M -$93.8M
FY 2024 $310.2M $8.3M 98.0% — $20.9M -$81.6M
FY 2023 $249.4M $15.5M — — $2.9M -$73.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IMCR // BETA —
TSHA // BETA —